» Articles » PMID: 25111856

Risks and Effectiveness of Compounded Bioidentical Hormone Therapy: a Case Series

Overview
Date 2014 Aug 12
PMID 25111856
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

After the publication of the Women's Health Initiative, attitudes towards management of menopausal symptoms changed dramatically. One alternative that has received much media attention is the use of bioidentical hormone therapy (BHT). The media and celebrity endorsements have promoted a number of misconceptions about the risks and benefits associated with the various forms of BHT. This article will review the available evidence regarding the safety and efficacy of BHT in comparison to conventional hormone therapy. We will also review several cases seen in our midlife women's referral clinics, which demonstrate concerns for the safety and efficacy of BHT, including unexplained endometrial cancer in otherwise healthy BHT users. Due to the lack of sufficient data to support the efficacy or safety of BHT, we recommend the use of United States Food and Drug Administration-approved regimens in the management of menopausal symptoms.

Citing Articles

Determination of estradiol and progesterone content in capsules and creams from compounding pharmacies.

Stanczyk F, Niu C, Azen C, Mirkin S, Amadio J Menopause. 2019; 26(9):966-971.

PMID: 31453957 PMC: 6738624. DOI: 10.1097/GME.0000000000001356.


Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptoms.

Constantine G, Revicki D, Kagan R, Simon J, Graham S, Bernick B Menopause. 2018; 26(5):513-519.

PMID: 30516713 PMC: 6493698. DOI: 10.1097/GME.0000000000001261.


Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms.

Simon J, Kaunitz A, Kroll R, Graham S, Bernick B, Mirkin S Menopause. 2018; 26(5):506-512.

PMID: 30489424 PMC: 6493699. DOI: 10.1097/GME.0000000000001271.


Increased Incidence of Endometrial Cancer Following the Women's Health Initiative: An Assessment of Risk Factors.

Constantine G, Kessler G, Graham S, Goldstein S J Womens Health (Larchmt). 2018; 28(2):237-243.

PMID: 30484734 PMC: 6390656. DOI: 10.1089/jwh.2018.6956.


Why women choose compounded bioidentical hormone therapy: lessons from a qualitative study of menopausal decision-making.

Thompson J, Ritenbaugh C, Nichter M BMC Womens Health. 2017; 17(1):97.

PMID: 28969624 PMC: 5625649. DOI: 10.1186/s12905-017-0449-0.